Bouvet (BOUV)
Oslo Stock Exchange · Norway · prices in NOK · close of 23 Oct 2026
Key indicators
| Last close | NOK 51.90 |
|---|---|
| 52-week range | 42.15 – 66.50 |
| Return, 1 month / 3 months | +10.9% / +17.4% |
| Return, 1 year / 3 years | −14.4% / +15.3% |
| Trend | Uptrend |
| RSI (14) | 72 |
| Volatility (1 year) | 30.2% |
| Worst drawdown (1 year) | -30.9% |
| Average daily value traded | 7.02M NOK |
| Dividend yield | 7.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bouvet is a Norwegian information technology consultancy based in Oslo. The company helps organisations with digitalisation, offering advisory services, system development, integration and cloud-related work. Its customers are mainly businesses and public sector bodies in Norway, who use Bouvet's consultants to design, build and maintain their digital solutions and to support their internal technology teams. Bouvet works closely with clients on projects that combine software engineering with advice on how to modernise their systems and ways of working.
On this site Bouvet appears as a stock on the Oslo Stock Exchange (Norway), code BOUV, with prices in Norwegian kroner (NOK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bouvet (BOUV) trades on the Oslo Stock Exchange in Norway. It last closed at NOK 51.90 on 23 October 2026.
Its price-based Market X-Ray is 62 out of 100 (a fair price profile), ranking 101 of 294 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 14.4% and over the last three months it rose 17.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Oslo Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 60 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 9.2% | ||
| From 52-week high | -21.2% | ||
| Momentum | 60 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 17.4% | ||
| 6-month return | 7.9% | ||
| 12-month return, skipping the last month | -22.8% | ||
| Stability (higher is calmer) | 58 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 30.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -30.9% | ||
| Liquidity | 67 · Fair | Moderate trading activity. | |
| Average daily value traded | 7.02M NOK | ||
| Zero-volume days | 0.0% | ||
| Income | 78 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 7.1% | ||
| Years with dividends | 6 |
Strengths
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +7.9% |
|---|---|
| 1 month | +10.9% |
| 3 months | +17.4% |
| 6 months | +7.9% |
| 1 year | −14.4% |
| 3 years | +15.3% |
| 5 years | +6.2% |
Signals
| 50-day / 200-day average | 48.12 / 47.51 |
|---|---|
| Golden / death cross (60 days) | Golden, 4 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.38 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 May 2026 | NOK 3.0000 |
| 13 Nov 2025 | NOK 0.7000 |
| 8 May 2025 | NOK 3.0000 |
| 14 Nov 2024 | NOK 1.0000 |
| 23 May 2024 | NOK 2.6000 |
| 13 Nov 2023 | NOK 0.5500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Oslo Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.